AVXL vs BIIB
AVXL: Anavex Life Sciences is a clinical-stage biotech developing oral, small-molecule sigma-1 receptor agonists to treat neurodegenerative and neurodevelopmental CNS disorders. BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA.
Side-by-side fundamentals
| Metric | AVXL | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.54 | $218.43 | |
| Market cap | $143M | $32.2B | |
| P/E as of 2026-10-08 | n/a | 38.68 | |
| Net margin FY2025, SEC XBRL | n/a | +13.1% | |
| Operating margin FY2021, SEC XBRL | n/a | +25.9% | |
| ROE FY2025, SEC XBRL | -48.9% | +7.1% | BIIB higher |
| ROA FY2025, SEC XBRL | -44.7% | +4.4% | BIIB higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.43 | AVXL lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +0.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.35 | 0.51 | |
| 1-year return as of 2026-10-08 close | -84.4% | +44.7% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.